Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Dersimelagon on QT/QTc Interval in Healthy Subjects
NCT05241535Phase 1Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Jan 2022
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of dersimelagon in erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) (3 arms), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoint: Placebo-corrected, baseline-adjusted QTcF interval at 24 hours. Started Jan 2022; status: completed.
02
Drugs
dersimelagon
03
Conditions
erythropoietic protoporphyria (EPP)X-linked protoporphyria (XLP)
Beyond the preview
Go deeper on NCT05241535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05241535.